Multiple Sclerosis
An immune attack on the insulation around nerve fibres. One region — the MHC — carries by far the largest inherited effect, and everything else, including the variant here, is part of a long tail of small ones.
What this condition connects to
Solid lines are connections this site curates. Dashed lines mean the two ends share a research paper — worth knowing, and not a claim that one explains the other.
Multiple sclerosis is a disease of the central nervous system in which the immune system attacks myelin, the insulating sheath around nerve fibres. The damage disrupts signalling, which produces episodes of neurological disturbance — vision loss, weakness, numbness, imbalance — and, over years, accumulating disability in many patients.
The shape of the genetics
MS runs in families more than chance explains, and studies of families confirmed early that variation within the major histocompatibility complex exerts the greatest individual effect on risk — the MHC being the region that determines what the immune system treats as foreign.
Everything else is a long tail. Genome-wide studies have added many further risk loci, each contributing modestly, and the picture is of a disease driven by many immune variants acting together rather than by any single gene.
The variant here
rs2300747 is recorded near CD58 from a 2009 meta-analysis of genome-wide scans: 2,624 people with MS and 7,220 controls, with replication in 2,215 further patients and 2,116 controls. That study's own headline findings were new susceptibility loci at TNFRSF1A, IRF8 and CD6 — all immune genes, and one of them, TNFRSF1A, carrying both a common variant of modest effect (odds ratio 1.2) and a rarer coding variant with a stronger one (frequency 0.02, odds ratio 1.6).
CD58 is an immune adhesion molecule involved in how T cells are activated and regulated, which is the kind of place MS variants tend to be.
What this cannot tell you
Whether you will develop MS, when, or how it will behave. Diagnosis is made from the pattern of neurological episodes, MRI findings and, often, examination of spinal fluid — using criteria designed to demonstrate that lesions are separated in space and in time. No genotype is part of that, and none predicts the course.
What has changed the disease is treatment: a range of disease-modifying therapies now reduce relapses and, started early, change the long-term trajectory. That is where the meaningful decisions are, and they are made from clinical and imaging findings.
New neurological symptoms lasting more than a day — particularly loss of vision in one eye, double vision, numbness spreading over hours, or weakness — deserve prompt assessment. Nothing on this page substitutes for that.
Positions joined since this page was written
What this is The text above discusses the variants this page was written around. Since then the catalogue has joined 13 more positions to it, by shared trait or shared paper. They are listed here by the paper each came from; the text does not describe them, and each variant page carries that study's own record.
Verma A et al. 2024, Science (New York, N.Y.) rs141495019 (RAD17), rs915504830 (ANKFN1), rs184104263 (near CEP162), rs559664213 (near LRATD1), rs150626530 (SLIT3), rs368479978 (GSTM5), rs570181105 (IL12A-AS1) — PMID:39024449
Shigesi N et al. 2025, Human reproduction (Oxford, England) rs61780263 (near EXTL2), rs17124032 (HISLA), rs7584894 (SP140) — PMID:40262193
Andlauer TFM et al. 2020, BMC medicine rs886401 (CCHCR1), rs17205731 (near HLA-DQB1), rs28746882 (near HLA-DQB1) — PMID:33143745
In the news
2026-09-07 · Genome-wide association analyses highlight the neuronal contribution to multiple sclerosis susceptibility. Nature Genetics. 2026. PMID:42706309 (companion paper PMID:42706308)
Two 2026 MS genetics studies point past the immune system, toward neurons themselves
Multiple sclerosis genetics has historically pointed almost entirely at immune cells and microglia. Two companion 2026 papers push the story further. The first, a multi-ancestry GWAS of 20,831 MS cases and 729,220 controls, found 236 susceptibility variants outside the MHC region (4 newly reported) and, integrating single-cell data from blood and brain, identified inhibitory neurons -- not just immune cells -- as a key target cell type for MS risk variants. Seven loci showed altered expression specifically in inhibitory neurons, including this site's own existing STAT3 variant (rs1026916): the new study adds that STAT3 is also linked to cognition and white matter integrity in people without MS, and to higher serum neurofilament light levels in people with MS -- suggesting MS susceptibility may partly reflect how resilient the nervous system itself is to inflammatory damage, not only how aggressive the immune attack is. The companion paper, a cross-population meta-analysis of 29,374 cases and 1,843,563 controls across 4 ancestries (including the first sizeable Japanese MS GWAS, 688 cases), found 22 further novel loci and a population-specific risk variant at 11q24 in the Japanese cohort, with spatial transcriptomics showing genetic risk concentrated in T helper cells, regulatory T cells and endothelial cells. This site's multiple sclerosis page carries 107 variants; neither paper's new loci were yet indexed in GWAS Catalog with rsID-level records at the time of writing, so this entry adds context to the existing STAT3 variant rather than introducing unverified new variant pages.
2026-02-19 · Schmidt A, et al., Nature 2026, PMID:41714741
Host control of persistent Epstein-Barr virus infection
Epstein-Barr virus infects roughly 90-95% of people and stays for life in B cells. This study read EBV out of ordinary blood-based genome sequencing: EBV reads turned up in 16.2% of 486,315 UK Biobank participants and 21.8% of 336,123 All of Us participants, tracking higher viral load in blood cells, and were more common with HIV infection, immunosuppressive drugs and current smoking. Genome-wide, the strongest signals were in the MHC — 54 independent HLA alleles across classes I and II — plus 27 regions outside it, with an interaction between HLA class I alleles and the ERAP2 locus. People with EBV-associated diseases carried a higher polygenic burden of the EBV-positive signal: at MHC class I in multiple sclerosis (driven by HLA-A*02:01) and at MHC class II in rheumatoid arthritis, with polygenic overlap also seen for inflammatory bowel disease, hypothyroidism and type 1 diabetes. Four of the study's non-MHC positions are already on this site — rs13098877 (LPP), rs884186 (KSR1), rs9828869 (near ILDR1) and rs34557412 (TNFRSF13B) — the last also linked here to lymphocyte count. PMID:41714741.
From our blog
Clinical detail
Architecture. Family studies established that genetic factors account for much of the increased frequency of MS in relatives of affected individuals, with the MHC exerting the largest single effect — the class II haplotype containing HLA-DRB1 being the long-established primary association. Beyond it, genome-wide studies have identified a large number of loci of modest effect, concentrated in genes with immune functions, consistent with a primary role for cell-mediated immune mechanisms.
The source study. The 2009 meta-analysis combined genome-wide scans totalling 2,624 subjects with MS and 7,220 controls, with replication in 2,215 patients and 2,116 controls, validating TNFRSF1A (combined P = 1.59 x 10-11), IRF8 (P = 3.73 x 10-9) and CD6 (P = 3.79 x 10-9). TNFRSF1A harbours two independent susceptibility alleles: rs1800693, common with an odds ratio of 1.2, and rs4149584, a non-synonymous variant at frequency 0.02 with an odds ratio of 1.6. The susceptibility allele near IRF8 was associated with higher expression of interferon-response genes in people with MS. rs2300747 near CD58 is recorded against this analysis.
Clinical position. Diagnosis follows the McDonald criteria: clinical episodes plus MRI evidence of lesions disseminated in space and time, supported where needed by cerebrospinal fluid oligoclonal bands. Management is disease-modifying therapy selected by disease activity and risk tolerance, alongside symptomatic and rehabilitative care. Genotype has no role in diagnosis, prognosis or treatment selection; HLA associations are research and epidemiological tools.
Related variants MyGeneLog™ checks for
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Multiple Sclerosis comes down to these specific, well-studied positions — not a diagnosis. 120 positions are linked to this page; the ones this page's own text discusses are shown first.
Which ancestries this evidence comes from
The studies behind these variants recruited participants from different ancestries — a result found in one population doesn't always transfer to another. Based on 107 of 120 linked studies with a resolved discovery ancestry.
Pharmacogenomics notes
Research-derived gene–drug associations only — not a prescription, dosing guide, or medical advice. Always follow your prescriber's guidance.
| Gene | Drug | What the research shows |
|---|---|---|
| CYP2C9 | Siponimod | Siponimod is one of the few medicines a person cannot be prescribed at all without a genetic test first. CYP2C9 clears it, and someone carrying two copies of the least-active form — the *3/*3 genotype, roughly one person in 250 of European ancestry — is exposed to about four times as much drug as a normal metaboliser. The US label makes that genotype an outright contraindication and halves the maintenance dose for two of the intermediate genotypes. Genotyping before the first dose is a requirement rather than a recommendation, which is what separates this from almost everything else on this site: here the test is part of the prescription. (US prescribing information for MAYZENT (siponimod). CPIC lists the pair at level A; the requirement to genotype comes from the label, not from a CPIC guideline.) |
Sources
Quoting this page
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Multiple Sclerosis. MyGeneLog™. https://www.mygenelog.com/conditions/multiple-sclerosis
Questions about Multiple Sclerosis
Can genetics tell me whether I will get MS?
No. Even the MHC — by far the largest inherited effect — is carried by many people who never develop MS. Diagnosis is made from neurological episodes, MRI and spinal fluid, never from a genotype.
Why do so many MS genes turn out to be immune genes?
Because that is what the disease is. The variants cluster in genes regulating T cells and interferon signalling, which is the strongest available argument that MS is driven by cell-mediated immunity rather than by something primarily neurological.
What about vitamin D and Epstein-Barr virus?
Both are part of the environmental picture that genetics does not explain: the disease is more common further from the equator, and EBV infection is now regarded as necessary though far from sufficient. Neither is settled enough to act on beyond ordinary health advice.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog™. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.